Cetuximab, marketed as Erbitux, is one of the key therapies for metastatic colorectal cancer, yet the cancer still returns in some patients, shortening overall survival. A new study may help explain why. Key proteins, known as epidermal growth factor receptors (EGFR), are regulated, leading to resistance.
"Our study investigated the role of extracellular methylation in EGFR signaling, and unexpectedly discovered new information about how EGFR renders cancer cells resistant to cetuximab antibody therapy," said Mien Chie Hung, Ph.D., chair of Molecular and Cellular Oncology at The University of Texas MD Anderson Cancer Center.